Comparison
BPC-157 vs Thymosin Beta-4
The two halves of the repair pairing, compared instead of combined. This is also where the TB-500 naming confusion does the most damage.
Thymosin Beta-4 is the full 43-amino-acid protein. TB-500 is a synthetic fragment of it, and the two names are used interchangeably in this market despite not being the same molecule. Most material sold as TB-500 is the fragment; most of the research cited in support is on the full protein.
Against that, BPC-157 is a fifteen-amino-acid sequence derived from a protein in human gastric juice — with its own body of animal work on tendon — ligament and gut repair.
Both rest on preclinical evidence. People choose between them on proposed mechanism, angiogenesis against cell migration, and that distinction comes from animal models rather than from any study that put the two side by side.
| Attribute | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| What it is | 15-amino-acid synthetic sequence | 43-amino-acid protein |
| Evidence level | Preclinical | Clinical |
| Proposed mechanism | Angiogenesis, growth factor pathways | Cell migration, actin regulation |
| Dosing frequency | Once or twice daily | Weekly |
| Dose scale | Micrograms | Milligrams |
| Also sold as | PL 14736, Pentadecapeptide BPC 157 | TB-500, the fragment, not the protein |
Things worth knowing
- The naming problem is the most important thing on this page. Buy "TB-500" and cite Thymosin Beta-4 research and you are citing work on a different molecule. No vendor labels the difference reliably.
- The dose scales sit a factor of a thousand apart. That is exactly the gap that turns a copied protocol into a serious error when nobody re-reads the unit.
- In practice these two are run together far more often than chosen between. The stack page covers what that involves.
Full profile
BPC-157
A synthetic 15-amino-acid peptide studied in animals for effects on tendon, ligament and gut tissue repair. No completed human trials.
Full profile
Thymosin Beta-4
The full 43-amino-acid protein that TB-500 is a fragment of. It reached phase 2 trials in humans. TB-500 never has.
Related
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.